TScan Therapeutics (NASDAQ:TCRX) Earns Buy Rating from HC Wainwright

TScan Therapeutics (NASDAQ:TCRX)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a note issued to investors on Wednesday,Benzinga reports. They currently have a $15.00 price objective on the stock. HC Wainwright’s price target would suggest a potential upside of 350.45% from the company’s previous close.

TCRX has been the subject of a number of other reports. Needham & Company LLC restated a “buy” rating and set a $11.00 target price on shares of TScan Therapeutics in a research report on Tuesday, November 12th. Wedbush reiterated an “outperform” rating and set a $7.00 price objective (down previously from $10.00) on shares of TScan Therapeutics in a research note on Tuesday.

TScan Therapeutics Price Performance

Shares of TCRX stock opened at $3.33 on Wednesday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.56 and a current ratio of 9.56. TScan Therapeutics has a fifty-two week low of $3.20 and a fifty-two week high of $9.69. The firm has a market capitalization of $177.73 million, a price-to-earnings ratio of -3.14 and a beta of 0.79. The stock’s 50-day simple moving average is $4.96 and its 200-day simple moving average is $5.95.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.03. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. The firm had revenue of $1.05 million during the quarter, compared to analysts’ expectations of $2.86 million. As a group, equities analysts forecast that TScan Therapeutics will post -1.12 earnings per share for the current fiscal year.

Insider Buying and Selling at TScan Therapeutics

In other TScan Therapeutics news, Director Barbara Klencke purchased 5,000 shares of the stock in a transaction on Monday, September 23rd. The shares were bought at an average price of $5.29 per share, for a total transaction of $26,450.00. Following the completion of the transaction, the director now owns 45,000 shares of the company’s stock, valued at $238,050. This trade represents a 12.50 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. 2.76% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Barclays PLC lifted its position in shares of TScan Therapeutics by 341.1% in the third quarter. Barclays PLC now owns 58,067 shares of the company’s stock valued at $289,000 after acquiring an additional 44,903 shares in the last quarter. Geode Capital Management LLC raised its stake in TScan Therapeutics by 8.1% in the 3rd quarter. Geode Capital Management LLC now owns 973,466 shares of the company’s stock valued at $4,849,000 after purchasing an additional 72,967 shares during the last quarter. XTX Topco Ltd purchased a new position in TScan Therapeutics in the 3rd quarter valued at $112,000. Wellington Management Group LLP boosted its stake in TScan Therapeutics by 38.9% during the 3rd quarter. Wellington Management Group LLP now owns 126,345 shares of the company’s stock worth $629,000 after purchasing an additional 35,404 shares during the last quarter. Finally, State Street Corp grew its holdings in shares of TScan Therapeutics by 24.4% during the third quarter. State Street Corp now owns 756,499 shares of the company’s stock worth $3,767,000 after buying an additional 148,414 shares in the last quarter. 82.83% of the stock is owned by institutional investors and hedge funds.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.